Abstract

Aim: To evaluate demografic features, treatment indications, respond to the treatment of 56 chronic lymphocytic leukemia (CLL) patients observed at our department of Hematology, Izmir Bozyaka Traning and Research Hospital. Material and Method: Data of 56 CLL patients were evaluated retrospectively. Findings: Twenty four patients (%42.9) were female, and 32 patients (%57.1) were male. The average age of the patients was 65 years old. While 23 patients recieved treatment, 33 patients were observed only. Five patients were treated by chlorambusil, 5 patient by cyclophosphamid-fludarabine therapy, and 13 patients were treated by rituximab-cyclophosphamid-fludarabine therapy. The median survival was 120 months. Four patients died because of CLL, and 2 patients died due to the other reasons.